18 Jul Nanoscope Therapeutics
Samarendra Mohanty, Ph.D., President
Oct. 6 | 12:15pm | FLW Ballroom G
Dallas, TX
(Private)
Inherited retinal dystrophies (IRDs) are devastating neurodegenerative conditions resulting in progressive, permanent vision loss. Over 8000 different mutations in more than 300 genes cause IRDs. No effective treatment for IRD patients with severe vision loss has been approved to date. Nanoscope Therapeutics was founded in Dallas (TX) to change that by advancing a novel gene therapy as a life-changing treatment for these patients, regardless of mutation, leaving no patient behind. Nanoscope’s clinical pipeline aims to provide return-to-life vision restoration in patients with Retinitis Pigmentosa (RP), Stargardt Macular Degeneration (SD), which account for over 80% of IRDs. Nanoscope has received Orphan Drug and Fast Track designations from the FDA for MCO-010 (sonpiretigene isteparvovec) in RP and SD. Following positive end-of-study results from the RESTORE multicenter, randomized, double-masked, sham-controlled clinical trial for RP, the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in 2025.
